BRIEF-Alterity Reports Positive Phase 2 Data for ATH434 in MSA, Shows Clinical Benefit and Biomarker Impact

Reuters
Jul 28
BRIEF-Alterity Reports Positive Phase 2 Data for ATH434 in MSA, Shows Clinical Benefit and Biomarker Impact

July 28 (Reuters) - Alterity Therapeutics Ltd ATH.AX:

  • ALTERITY THERAPEUTICS REPORTS POSITIVE TOPLINE DATA FROM OPEN-LABEL PHASE 2 CLINICAL TRIAL OF ATH434 IN MULTIPLE SYSTEM ATROPHY

  • ALTERITY THERAPEUTICS LTD - ATH434 WELL-TOLERATED WITH FAVORABLE SAFETY PROFILE

  • ALTERITY THERAPEUTICS LTD - NO SERIOUS ADVERSE EVENTS REPORTED FOR ATH434

  • ALTERITY THERAPEUTICS LTD - ATH434 SHOWS CLINICAL BENEFIT AND STABILIZES SYMPTOMS

Source text: ID:nGNX1dctqJ

Further company coverage: ATH.AX

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10